Latest Articlesddd
As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the …
Merck’s (MRK) anti-PD-1 drug Keytruda® (pembrolizumab) is approved for many, many cancers. Yet, it is fair …
Additional Combination Treatment with Vectibix for Metastatic Colorectal Cancer (mCRC) The Old Drug: VECTIBIX …
On June 22, 2017, the U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan Hycela™. …
The most important last barrier to cross or dismantle for drug developers is the approval of …
IMPRESSIVE RESULTS? Bellicum Pharmaceuticals’ (BLCM) drug BPX-501 is described as a safe and effective product that …
Portola (PTLA) announced that the U.S. Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban), the …
We examined many explanations about the rallying in the biotech stocks, including the reports stating that …
Prohost Letter #411 SOME STOCK RALLYING NEWS - Under normal conditions, some good news should rally …
Since Regulus’ (RGLS) lead candidate drug RG101 for HCV was put on clinical hold by the …
Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of …
Juno’s (JUNO) JCAR017 and JCAR014 are chimeric antigen receptor T cell (CAR-T) product candidates that target …
AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was …
As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology …
Alnylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the …
It is obvious that the CAR-T approach to cancer treatment is here to stay and to …
Array Biopharma (ARRY) and Bristol-Myers Squibb (BMY) announced a clinical research collaboration to investigate the safety, …
Prohost Letter #409 ASCO The American Society of Clinical Oncology (ASCO) meeting is around the corner. …
GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most …
Amgen’s (AMGN) and UCB's drug Evenity (romosozumab), which, in long and large 24 months of clinical …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
